Showing 1 - 10 of 20
be TRIPS compatible to exclude micro-organisms from patenting. This is the report of the Group. …
Persistent link: https://www.econbiz.de/10005487869
A brief but comprehensive overview of linkages between higher education and the high tech sector and study the major linkages in India is provided. It is found that the links outside of the labor market are weak. This is attributed to a regulatory structure that separates research from the...
Persistent link: https://www.econbiz.de/10005012253
In this paper we attempt to provide a comprehensive understanding of the drivers of academic research and patenting in …
Persistent link: https://www.econbiz.de/10008620630
The report of the Expert Committee provides a broad overarching framework for guiding the policies governing the production and use of different forms of energy from various sources. It makes specific recommendations on a very large range of issues. The report is a valuable input into policy...
Persistent link: https://www.econbiz.de/10005528125
The paper offers some reflections on technological capability building in the context of low-income developing countries. The issue is of particular concern, especially in an economic climate of liberalisation hostile to direct state intervention, at a time when the less developed countries are...
Persistent link: https://www.econbiz.de/10005487632
scenario. It also discusses the current situation regarding patenting biopharmaceuticals in India. [GIDR WP no. 168]. …
Persistent link: https://www.econbiz.de/10005487727
Three important aspects of the Canadian pharmaceutical industry-viz. compulsory licence, price control on patented drugs and the R&D scenario. Unlike other developed countries, which have adopted the route of providing higher Intellectual Property Rights (IPR) protection to promote the growth of...
Persistent link: https://www.econbiz.de/10005487733
The focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals from 1 January, 2005. WIll this lead increase in resources deveoted to R and D by Indian companies for the development of new drugs more suited to the needs of India and other...
Persistent link: https://www.econbiz.de/10004988399
The paper seeks to prove the point that the Indian OTC derivatives markets, unlike many other jurisdictions, are well regulated. Only contracts where one party to the contract is an RBI regulated entity are considered legally valid in India. A good reporting system and a post-trade clearing and...
Persistent link: https://www.econbiz.de/10008509776
There is a strong feeling among especially the West that India is becoming very innovative. The study will take the reader through the empirical evidence on whether this is indeed the case since the reform process of 1991. The actual innovative performance of India’s economy since...
Persistent link: https://www.econbiz.de/10008512436